Market Overview

Evelo Biosciences' Potential Is 'Significant,' Says Bullish Morgan Stanley

Evelo Biosciences' Potential Is 'Significant,' Says Bullish Morgan Stanley
Related EVLO
46 Biggest Movers From Yesterday
38 Stocks Moving In Monday's Mid-Day Session

Evelo Biosciences Inc (NASDAQ: EVLO), a clinical stage biotechnology company that focuses on mining the gut for therapetuics that can modulate the immune system, boasts "significant" platform potential, according to Morgan Stanley.

The Analyst

Morgan Stanley's Matthew Harrison initiated coverage of Evelo Biosciences with an Overweight rating and $29 price target.

The Thesis

Evelo Biosciences develops monoclonal microbials, which are pharmaceutical compositions of naturally occurring microbes, Harrison said in the initiation note. The company is using its platform to screen the gut for microbes that could impact immune responses and its first program, EDP1066, will report initial data in the first half of 2019, the analyst said.

Preclinical information supports the view that the therapy has at least the potential clinical impact of strong steroid and biologic treatments, Harrison said. 

Two notable investor concerns surround Evelo Biosciences, the analyst said:

  • Prior microbiome companies haven't shown significant improvements in clinical trials.
  • Management's screening platform isn't robust enough to identify the right target for therapeutic intervention.

Evelo's focus on developing microbes from natural activity in the gut differs from other companies that work on on a repopulation of the gut, which is more complicated to modulate disease, Harrison said. It would difficult for the company to improve investor sentiment until it can demonstrate an initial proof-of-concept, he said.

Phase 1 data in the first half of 2019 is as a "key catalyst" for the stock, the analyst said. 

Price Action

Evelo Biosciences shares were trading 3 percent higher premarket Monday. 

Related Links:

The Week Ahead In Biotech: ASCO Presentations Dominate The Headlines

TapImmune Poised To Become A Cell Therapy Leader, WBB Securities Says In Upgrade

Latest Ratings for EVLO

Oct 2018Morgan StanleyMaintainsOverweightOverweight
Oct 2018Morgan StanleyMaintainsOverweightOverweight
Jun 2018Morgan StanleyInitiates Coverage OnOverweight

View More Analyst Ratings for EVLO
View the Latest Analyst Ratings

Posted-In: Matthew Harrison MicrobialsAnalyst Color Biotech Price Target Initiation Analyst Ratings General Best of Benzinga


Related Articles (EVLO)

View Comments and Join the Discussion!

Latest Ratings

View the Latest Analytics Ratings
Don't Miss Out!
Join Our Newsletter
Subscribe to:
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
Your weekly roundup of hot topics in the exciting world of fintech.
Thank You
for registering for Benzinga’s newsletters and alerts.
• The Daily Analysts Ratings email will be received daily between 7am and 10am.
• The Market in 5 Minutes email will be received daily between 7am and 8am.
• The Fintech Focus email will be received every Friday between 2pm and 5pm.

Stifel 'Highly Encouraged' After Chat With Under Armour, Raises Price Target

28 Stocks Moving In Monday's Pre-Market Session